REVIEW ARTICLE

Effects of the Phytopolyphenol Resveratrol as a Therapeutic Adjunct in Sickle Cell Disease (SCD) and 𝛽-thalassemia Management

Orien L Tulp.1,2,3,4 Syed A A Rizvi.1,6 Uzoamaka Nwokorie.1,5 George P Einstein.1,2 

• .1University of Science Arts and Technology, Montserrat, Colleges of Medicine and Graduate Studies 
• .2The Einstein Medical Institute, North Palm Beach Florida 
• .3East West College of Natural Medicine, Sarasota FL 
• .4Universidad de Sevilla, Seville, Spain 
• .5National Hospital, Abuja Nigeria 6Larkin Hospital, Miami FL USA
•  

Corresponding Author: Orien L Tulp, Professor of Medicine and Graduate Studies, University of Science Arts and technology, Montserrat, British West Indies, PO Box 506, MSR1110; East West College of Natural Medicine, Sarasota, FL USA. 34234, and Universidad de Sevilla, Seville, Spain, 41004. E-mail: [email protected], [email protected]

Received: July 03, 2025                                   Published: July 22, 2025

Citation: Tulp OL. Can trans-3’5’4-trihydroxystilbene (resveratrol) become an effective adjunct in the treatment of sickle cell disease? Int J Complement Intern Med. 2025;6(3):399–408. DOI: 10. 58349/IJCIM. 3. 6. 2025. 00156

Copyright: ©2025 Tulp OL. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.

Abstract 

Sickle Cell Disease (SCD) and 𝛽-thalassemia are among the most common forms of hemoglobinopathy and life-threatening genetic diseases worldwide, necessitating the need for more effective and cost-effective therapies to treat these disorders. SCD occurs due to a single amino acid substitution of Valine for Glutamic acid in the β-chain subunit to form the sickle cell (HbS) variant. Hydroxyurea (HU) is currently the only disease modifying drug approved for SCD, while advances in gene editing processes have also recently been introduced but their clinical use is not yet widely therapeutically available. HU is a ribonucleotide reductase inhibitor and fetal hemoglobin (Hb F; α2γ2) inducer that can reduce the clinical symptoms and frequency of hospitalizations for SCD, but it falls short of being a curative therapy and must be continued indefinitely in SCD patients. The efficacy of HU in the management of thalassemia and SCD is generally attributed to its limited ability to boost the levels of fetal hemoglobin (Hb F, α2γ2) in RBCs, and provide a partially protective mechanism for the sickle reaction which ultimately damages the blood vessels, thereby contributory to the major pathophysiologic clinical signs and symptoms and decreased lifespan associated with the SCD disorder. Thus, we propose that partial amelioration of SCD hemoglobin (HbS) with fetal hemoglobin via pharmacologic effects of trans-resveratrol (RSV), a naturally occurring phytochemical, may become a benefit to the patient since HbF is not susceptible to the disordered intracellular VO2-linked hemoglobin (HbS) polymerization often referred to as the sickling reaction during HbS deoxygenation. Accordingly, RSV would thereby limit the subsequent vessel damage due to small vessel occlusion which occurs due to HbS and thus should be able to improve patient outcomes by reducing the magnitude of ROS damage in addition to diminishing the ratio of cells that are susceptible to sickling reactions vs. the sickle-protected fetal-hemoglobin containing cells. In addition, RSV may also provide beneficial impacts on the sickle cell anemia (SCA) by prolonging erytrocyte survival that typically accompanies the disorder. Thus, RSV may also be able to partially correct the effects linked to the globin chain imbalance in SCD patients, while at the same time facilitating oxygen transport to myoglobin in peripheral tissues due to a more favorable oxygendelivering capacity than is observed in adult hemoglobin. Thus, in conclusion, RSV may be a useful and cost-effective phytochemical adjunct in the treatment of SCD and β-thalassemia, the two major heritable hemoglobinopathies of humans. 

Keywords: resveratrol, hydroxyurea, sickle cell disease, antioxidants, sirtuins, Nrf2 Activation

References 

1. Takaoka M. Resveratrol, a new phenolic compound, from Veratrum grandiflorum. J Chem Soc Jpn. 1939;60:1090–1100. 

2. Detampel P, Beck M, Krahenbuhl S, et al. Drug interaction potential of resveratrol. Drug Metab Rev. 2012;44(3):253–265. 

3. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339(8808):1523– 1526. 

4. Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? Adv Nutr Int Rev J. 2016;7(4):706–718. 

5. Camont L, Cottart CH, Rhayem Y, et al. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Analytica Chimica Acta. 634(1):121–128. 

6. Uzoamaka Nwokorie, George P Einstein, Orien L Tulp. Use of trans3’5’4-trihydroxystilbene (Resveratrol) as an adjunct in the treatment of Sickle Cell Disease. FASEB Journal. 2021;35(S1). 

7. Cardile V, Chillemi R, Lombardo L, et al. Antiproliferative activity of methylated analogues of E- and Z-resveratrol. Z Nat C J Biosci. 2007;62:189–195. 

8. Nawaz W, Zhou Z, Deng S, et al. Therapeutic Versatility of Resveratrol Derivatives. Nutrients. 2017;9:1188. 

9. Li M, Kildegaard KR, Chen Y, et al. De novo production of resveratrol from glucose or ethanol by engineered Saccharomyces cerevisiae. Metab Eng. 2015;32:1–11.

10. Chen X, He H, Wang G, et al. Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. Biomed. Chromatogr. 2007;21(3):257–265. 

11. Colica C, Milanović M, Milić N, et al. A Systematic Review on Natural Antioxidant Properties of Resveratrol. Nat Prod Commun. 2018;13. 

12. Devlin TM. Textbook of Biochemistry with clinical correlations, 7th edn. ISBN: 978-0-470-28173-4. 2010. 

13. Localzo J, Harrison TR. Harrison’s Principles of Internal Medicine. 21st edn. (IBSN-10.1264268505: IBSN 13-978-1264268504. Publisher: McGraw Hill. NY. 2022. 

14. Kayle M, Blewer AL Pan W, et al. Morbidity and Mortality Weekly Report (MMWR): Birth Prevalence of Sickle Cell Disease and CountyLevel Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020. 2024;73(12);248–254. 

15. Agrawal RK, Patel RK, Shah V, et al. Hydroxyurea in Sickle Cell Disease: Drug Review. Indian J Hematol Blood Transfus. 2013;30(2):91–96. 

16. Bo S, Ciccone G, Castiglione A, et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem. 2013;20:1323– 1331. 

17. Pannu N, Bhatnagar A. Resveratrol: From enhanced biosynthesis and bioavailability to multitargeting chronic diseases. Biomed Pharm. 2019;109:2237–2251. 

18. Rodrigue CM, Arous N, Bachir D, et al. Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br J Haematol. 2001;113(2):500– 507. 

19. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506. 

20. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, et al. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res. 2010;54:7–16. 

21. Salehi B, Mishra AP, Nigam M, et al. Resveratrol: A Double-Edged Sword in Health Benefits. Biomedicines. 2018;6(3):91. 

22. Shaito A, Posafino AM, Younes N, et al. Potential Adverse Effects of Resveratrol: A Literature Review. Int J Mol Sci. 2020;21(6):2084. 

23. Walle T, Hsieh F, Delegge MH, et al. High Absorption but Very Low Bioavailability of Oral Resveratrol in Humans. Drug Metab Dispos. 2004;32(12):1377–1382. 

24. Zhang B, Xu Y, Lv H, et al. Intestinal pharmacokinetics of resveratrol and regulatory effects of resveratrol metabolites on gut barrier and gut microbiota. Food Chemistry. 2021;357;129532. 

25. Springer M, Moco S. Resveratrol and Its Human Metabolites—Effects on Metabolic Health and Obesity. Nutrients. 2019;11;11(1):143. 

26. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl. 1):S131–155. 

27. Intagliata S, Modica MN, Santagati LM, et al. Strategies to Improve Resveratrol Systemic and Topical Bioavailability: An Update. Antioxid (Basel) 2019;8(8):244. 

28. Wan S, Zhang L, Quan Y, et al. Resveratrol-loaded PLGA nanoparticles: Enhanced stability, solubility and bioactivity of resveratrol for nonalcoholic fatty liver disease therapy. R Soc Open Sci. 2018;5(11):181457. 

29. Howells LM, Berry DP, Elliott PJ, et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res. 2011;4(9):1419–1425. 

30. Ramli I, Posadino AM, Giordo R, et al. Effect of Resveratrol on Pregnancy, Prenatal Complications and Pregnancy-Associated Structure Alterations. Antioxidants (Basel). 2023;;12(2):341.

31. Mizuguchi Y, Hatakeyama H, Sueoka K, et al. Low dose resveratrol ameliorates mitochondrial respiratory dysfunction and enhances cellular reprogramming. Mitochondrion. 2017;34:43–48. 

32. Bourassa DJ, Tulp OL, Einstein GP. Electron Scavenging not Free Radical Scavenging by Fullereen Materials Protects Against Mitochondrial Oxidative Stress in Complex Organisms. ECPharmacology and Toxicology. 2020;8(6)::61–67. 

33. Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell. 2006;126(2):257–268. 

34. Tulp, OL. Effect of aging and obesity on parameters of insulin, T4/T3 ratios, metabolic rates, sirtuins and longevity in congenic LA/Ntul//- cp rats. Suntext review of medical and clinical research. 2024;5(4):212:1– 9. 

35. Cote CD. Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nat Med. 2015;21(5):498– 505. 

36. Wong RH, Nealon RS, Scholey A, et al. Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2016;26(5):393–399. 

37. Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim Pol. 2019;66(1):13–21. 

38. Berman AY, Motechin RA, Wiesenfeld MY, et al. The therapeutic potential of resveratrol: a review of clinical trials. Npj Precis Oncol. 2017;1:35. 

39. Tulp OL, Rizvi AA, Einstein GP. Low dose biophotonic treatment enhances oxygen saturation and hematologic parameters. Ch 11 in: Achievements and Challenges of Medicine and Medical Science. IBSN 978-93-48388-45-2. 2024. 

40. Manai F, Amadio M. Dimethyl Fumarate Triggers the Antioxidant Defense System in Human Retinal Endothelial Cells through Nrf2 Activation. Antioxidants (Basel). 2022;11(10):1924. 

41. FDA Newsroom. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. 2023. 

42. Ren Q, Hu Z, Jiang Y, et al. SIRT1 Protects Against Apoptosis by Promoting Autophagy in the Oxygen Glucose Deprivation/ReperfusionInduced Injury. Front Neurol. 2019;10:1289. 

43. Anvekar RA, Asciolla JJ, Missert DJ, et al. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol. 2011;1(34):34.